Fate Therapeutics Inc (FATE)

Sep 06, 2026

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits

Sep 06, 2026

Sep 04, 2026

Fate Therapeutics stock holds steady as investors watch cash runway and pipeline - AD HOC NEWS

Sep 04, 2026

Sep 03, 2026

FATE Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusPost-Earnings Drift - vinanet.vn

Sep 03, 2026

Sep 03, 2026

A lupus trial that could support approval is on Fate Therapeutics’ agenda Sept. 9. - Stock Titan

Sep 03, 2026

Sep 03, 2026

BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE - MarketBeat

Sep 03, 2026

Sep 03, 2026

Fate Therapeutics stock stabilizes after autoimmune CAR-T safety shock - ad-hoc-news.de

Sep 03, 2026

Sep 02, 2026

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE) - Seeking Alpha

Sep 02, 2026

Aug 30, 2026

574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat

Aug 30, 2026

Aug 27, 2026

487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC - MarketBeat

Aug 27, 2026

Aug 20, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Aug 20, 2026

Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026

Aug 16, 2026

Fate Therapeutics (FATE) Gains 1.98% to $2.57 as Stock Holds Above Key SupportStock News - dars.gov.et

Aug 16, 2026

Aug 16, 2026

Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE - MarketBeat

Aug 16, 2026

Aug 15, 2026

Fate Therapeutics (FATE) Rises 1.98% to $2.57 as it Approaches Key ResistanceAdvance Decline Line - vinanet.vn

Aug 15, 2026

Aug 15, 2026

Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat

Aug 15, 2026

Aug 14, 2026

Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Australia

Aug 14, 2026

Aug 14, 2026

Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $8 - Moomoo

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis - BioPharm International

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo - Moomoo

Aug 14, 2026

Aug 14, 2026

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics doses first patient in FT819 lupus trial - Investing.com

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics doses first patient in FT819 lupus trial By Investing.com - Investing.com Nigeria

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis - TradingView

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis - Quiver Quantitative

Aug 14, 2026

Aug 14, 2026

Fate Therapeutics' First FT819 Patient Went Home Same Day - Stock Titan

Aug 14, 2026

Aug 14, 2026

FATE THERAPEUTICSPATIENTS TO RECEIVE SINGLE 900 MLN-CELL DOSE OF FT819; PRIMARY ENDPOINT AT WEEK 26 - webull.com

Aug 14, 2026

Aug 13, 2026

FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5 - Bitget

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo! Finance Canada

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics Reports Q2 2026 10-Q Filing Highlighting iPSC Pipeline and Key Risks - Kalkine Media

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aug 13, 2026

Aug 13, 2026

Form 8K Fate Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics: Q2 Earnings Snapshot - marketscreener.com

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises - TradingView

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics Reports $30.2 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 13, 2026

Aug 13, 2026

Fate Therapeutics reports Q2 2026: $2.1M revenue, $30.2M net loss, cash $153.8M - TradingView

Aug 13, 2026

Aug 11, 2026

Fate Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - tradingview.com

Aug 11, 2026

Aug 11, 2026

Fate Therapeutics (FATE) Short Interest & Short Float | Updated Aug 2026 $FATE - MarketBeat

Aug 11, 2026

Aug 09, 2026

FATE Stock Price and Chart — NASDAQ:FATE - TradingView

Aug 09, 2026

Aug 08, 2026

Renaissance Technologies LLC Increases Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat

Aug 08, 2026

Aug 07, 2026

Don't Ignore The Insider Selling In Fate Therapeutics - webull.com

Aug 07, 2026

Aug 05, 2026

Fate Therapeutics (NASDAQ: FATE) CLO sells 38,800 shares to cover taxes - Stock Titan

Aug 05, 2026

Aug 05, 2026

Fate Therapeutics (FATE) CEO sells 43,947 shares to cover RSU tax - Stock Titan

Aug 05, 2026

Aug 04, 2026

FATE (FATE) insider files to sell 38,800 common shares on NASDAQ - Stock Titan

Aug 04, 2026

Aug 04, 2026

FATE (FATE) holder discloses 43,947-share potential sale and prior trade - Stock Titan

Aug 04, 2026

Aug 04, 2026

Fate Therapeutics (FATE) to Release Quarterly Earnings on Tuesday - MarketBeat

Aug 04, 2026

Aug 04, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)August 3, 2026 - marketscreener.com

Aug 04, 2026